Limitations: No participant was taking lipid-lowering medication, and diabetes was uncommon. 局限性:没有正在服用降脂药物的患者,也几乎没有糖尿病患者。
Lipid-lowering medication reduces blood cholesterol levels, an important risk factor for CVD. 调脂治疗降低血胆固醇水平,而后者是CVD的主要危险因素。
Subjects were not taking vascular active substance and lipid-lowering medication. 受试者未服用血管活性药物及降脂降压药物。
Methods: 1. Through the biggest drug test for mice, observation made fat away lipid-lowering capsule may produce acute toxicity reaction. Opposition fat away lipid-lowering medication safety capsule. 2. 方法:1.通过小鼠的最大给药量试验,观察立脂消降脂胶囊可能产生的急性毒性反应,对立脂消降脂胶囊的药物安全性进行初步研究。